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Abstract
Proteomic studies have increased our understanding of the molecular pathways affected in psychiatric disorders.
Mass spectrometry and two-dimensional gel electrophoresis analyses of post-mortem brain samples from psy-
chiatric patients have revealed effects on synaptic, cytoskeletal, antioxidant and mitochondrial protein networks.
Multiplex immunoassay proﬁling studies have found alterations in hormones, growth factors, transport and
inﬂammation-related proteins in serum and plasma from living ﬁrst-onset patients. Despite these advances,
there are still difﬁculties in translating these ﬁndings into platforms for improved treatment of patients and
for discovery of new drugs with better efﬁcacy and side effect proﬁles. This review describes how the next
phase of proteomic investigations in psychiatry should include stringent replication studies for validation of
biomarker candidates and functional follow-up studies which can be used to test the impact on physiological
function. All biomarker candidates should now be tested in series with traditional and emerging cell biological
approaches. This should include investigations of the effects of post-translational modiﬁcations, protein dy-
namics and network analyses using targeted proteomic approaches. Most importantly, there is still an urgent
need for development of disease-relevant cellular models for improved translation of proteomic ﬁndings into
a means of developing novel drug treatments for patients with these life-altering disorders.
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Introduction
Over the last decade, proteomics has gone through rapid
developments in many different areas. These include
improvements in mass spectrometry techniques, peptide
identiﬁcation algorithms, biostatistics and bioinformatics
applications. There is now considerable scope in applying
these methods to answer important medical issues. In
doing so, the advantage of proteomic methods over tra-
ditional targeted approaches lies in the unbiased nature
of looking globally at cellular system dynamics in disease
and healthy states. This is of interest as most medical
studies focus on single protein abnormalities rather than
considering the high interconnectivity of the proteome,
and that the whole network dynamics might be
hampered in the disease state.
There have been a number of recent advances
using novel proteomic proﬁling methods to uncover
the pathways affected in psychiatric disorders such as
schizophrenia. Until recently, studies of these conditions
using the long standing targeted methods have been
hampered due to the heterogeneous aetiology, presumed
polygenetic architecture (Stefansson et al., 2009; Group,
2011; Kim et al., 2011) and the emerging concept that
these are whole body diseases which can affect not just
the brain but multiple organ systems as well (Harris
et al., 2012). Current hypotheses now suggest that these
diseases can result from a complex interaction of genetic
predisposition and environmental factors, which ulti-
mately lead to the observed molecular alterations in the
brain and other parts of the body (Caspi et al., 2003;
Karg et al., 2011).
These interactions are dynamic in nature and are likely
to introduce numerous proteomic alterations that con-
verge on similar pathways. Likewise, increased risk for
a particular psychiatric disorder is more likely to be con-
ferred by the emergent properties of the pathway itself
rather than by a single gene product (Sullivan, 2012).
Therefore, application of multiplex proteomic proﬁling
methods seems especially suited to elucidating affected
pathways, furthering our understanding of the disease
mechanisms and facilitating drug discovery in psychiatric
disorders (Barabasi et al., 2011). This is also of importance
for the phenomenology of psychiatric disorders which are
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increasingly coming to be considered as a continuous
spectrum. The overlap of shared symptoms is likely to
be manifested at the level of protein networks compared
to similar genetic vulnerabilities.
Taking these factors into consideration, numerous
quantitative proteomic methods have already been ap-
plied for the study of different brain regions, peripheral
body tissues and ﬂuids which have been implicated in
psychiatric disorders. These studies initially involved
the use of two-dimensional polyacrylamide gel electro-
phoresis methods, and have been followed by a variety
of more in-depth mass spectrometry-based approaches.
In addition, multiplex immunoassay panels have been
used to investigate changes in the concentration of low-
abundance proteins such as cytokines, hormones and
growth factors in bio-ﬂuids, including serum and plasma.
The approach of proﬁling bio-ﬂuids is most likely to
lead to a biomarker signature with prognostic, diagnostic
and theranostic value, as these are readily accessible
and amenable for study in the clinical environment.
Ultimately, proteomic bio-ﬂuid signatures might be
used to enhance our knowledge of disease mechanisms
and drug actions and to derive new biomarker tests for
improved diagnosis, prediction of drug response and
for monitoring drug efﬁciency and side effects.
The aim of this review is to discuss the recent progress
on proteomic and cytomic methods and their application
to studies of the brain and peripheral systems. As the
brain presents unique challenges for proteomic analyses
due to its regional and cellular heterogeneity, as well as
its obvious inaccessibility in living patients, we will also
describe new approaches based on the systemic nature
of psychiatric disorders to circumvent these issues. Pro-
teomic and cytomic approaches will be described using
peripheral blood cells and reprogrammed skin cells,
both of which share many properties of neuronal cells
of the brain. We will also discuss the potential of using
such cell-based systems in combination with proteomic
biomarkers as novel pre-clinical models for use in drug
discovery.
Quantitative proteomic methods in psychiatric research
Current quantitative proteomics methods in psychiatric
research have mainly involved the measurement of rela-
tive protein abundances between different disease and
health states or the effects of different drug treatments
on proteomic proﬁles.
The ﬁrst generation of proteomic approaches em-
ployed two-dimensional gel electrophoresis (2-DE)
approaches such as difference gel electrophoresis
(2D-DIGE) or direct mass spectrometry-based methods
for simultaneous quantitation and identiﬁcation of poten-
tial protein biomarkers. These methods have been and are
still widely employed in psychiatric research. However,
this approach is limited in terms of the types of proteins
which can be identiﬁed and the capacity for comparing
large numbers of samples. To overcome these limitations,
direct mass spectrometry-based methods have been de-
veloped for simultaneous quantitation and identiﬁcation
of potential protein biomarkers. This has been facilitated
by technological advancements in mass spectrometer
design and by combining electrospray ionization (ESI)
or matrix-assisted laser desorption/ionization (MALDI)
ion sources with ion traps or quadrupole and time-of-
ﬂight (TOF) mass analysers.
In addition quantitative capacity has been enhanced
using label-free platforms such as liquid chromatography
mass spectrometry in expression mode (LC-MSE) (Levin
et al., 2011), the advances of travelling wave-based ion-
mobility separation coupled with mass spectrometry
(Bond et al., 2013), selected reaction monitoring (SRM)
(Kuhn et al., 2004) and sequential window acquisition
of all theoretical fragment-ion spectra (SWATH)
(Hopfgartner et al., 2012), and labelling methods includ-
ing isotope-coded afﬁnity tags (ICAT) (Gygi et al., 1999),
isotope tagging for relative and absolute quantitation
(iTRAQ) (DeSouza et al., 2005), and stable isotope label-
ling by amino acids in cell culture (SILAC) (Ong et al.,
2002). Multiplex immunoassay platforms have improved
in accuracy and throughput via developments using dye-
containing microspheres combined with ﬂow cytometric
analysis for simultaneous identiﬁcation and quantitation
of analytes (Liu et al., 2005) as well as in the development
of aptamer-based detection systems (Kraemer et al., 2011;
Yoshida et al., 2012). Nevertheless, the approaches have
mainly led to the identiﬁcation of changes in overall
levels of proteins, without offering novel insights into
changes in function at the systems level or taking post-
translational modiﬁcations into account. This is of great
importance as proteins are regulated in a systems biology
manner through interactions with other proteins or mol-
ecules in complex networks (Silverman and Loscalzo,
2012). The following two sections summarize the major
reproducible ﬁndings of these analyses in studies of psy-
chiatric disorders.
Summary of proteomic alterations in psychiatric
research
Brain tissue proﬁling
In psychiatric research, proteomic tissue proﬁling has
been predominantly used for analysis of brain regions
which have been implicated in disease (Table 1).
Most of these studies have led to identiﬁcation of pro-
teomic abnormalities in energy metabolism (aldolase,
fructose–bisphosphate, creatine kinase, enolase, lactate
dehydrogenase), oxidative stress (heat shock proteins,
peroxiredoxins, superoxide dismutase), synaptic trans-
mission (protein kinase C, inositol monophosphatase)
or cell maintenance and structure (alpha internexin,
neuroﬁlaments, dynamin, glial ﬁbrillary acidic protein,
actin and tubulin) (Johnston-Wilson et al., 2000;
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Table 1. Summary of brain proteomic studies in neuropsychiatric research. Included studies had at least 10 biological replicates in the disease group
Ref Brain region Samples/Disease Method Altered proteins CPA VD Linked pathways/biological functions
[1] PFC, BA10, gray matter 24 SZ, 23 BD, 19 MDD, 23 HC 2DE 8 NO NO Cytosolic and metabolism
[2] DLPFC, BA9, gray/white
matter
10 SZ vs. 10 SZ 2D-DIGE 215 NO NO Metabolism and oxidative stress
[3] ACC, BA24, gray matter 15 SZ vs. 15 BD vs. 15MDD vs. 15
HC
2DE 19 NO IB Mitochondrion and cytoskeleton
[4] ACC, BA24, gray matter 10 SZ vs. 10 SZ 2DE 39 NO TR Metabolism, oxidative stress, synaptic, signalling,
glial proteins
[5] DLPFC 17 SZ vs. 20 BD vs. 20 HC MALDI-TOF 24 peaks (21 SZ, 7 BD) NO NO Cell metabolism, signalling, chaperones
[6] DLPFC, BA9, gray matter 34 SZ vs. 32 BD vs. 30 HC 2DE 15 (SZ) +51 (BD) NO IB Septin family
[7] ACC, BA24, white matter 10 SZ vs. 10 HC 2DE 32 NO NO Cytoskeleton, metabolism
[8] Corpus callosum 11 SZ vs. 10 HC 2DE 64 NO NO Cytoskeleton, signal transduction, metabolism
[9] DLPFC, BA9, gray matter 10 SZ vs. 10 BD vs. 10 HC 2D-DIGE 96 NO TR, IB Synaptic, cytoskeletal proteins and metabolism
GELC-MS/
MS
56
[10] IC, gray matter, layer 2 12 SZ vs. 13 HC 2D-DIGE 57 NO NO Neuronal plasticity, neurite outgrowth, synaptic
proteins
[11] Hippocampus 20 SZ vs. 20 BD vs. 20 HC 2D-DIGE 108 SZ +165 BD YES NO Cytoskeleton, metabolism
[12] Thalamus 11 SZ vs. 8 HC ITRAQ, 2DE 41, 10 NO WB, FA Energymetabolism, oligodendrocytes, cytoskeleton
[13] DLPFC 11 MDD-NP, 12 MDD-P, 24 HC LC-MSE 28 (MDD-NP), 36 (MDD-P),
31 (MDD-NP vs. P)
NO IB, SRM, FA Energy metabolism, synaptic function
[14] DLPFC, BA9 10 SZ vs. 10 HC LC-MSE 34 NO IB Synaptogenesis, vesicle dynamics, energy buffering
systems
[15] DLPFC, BA9 10 SZ vs. 10 HC LC-MSE 53 YES FA Long-term potentiation, cellular assembly
organization, cytoskeleton
Ref=reference; PFC=prefrontal cortex; DLPFC=dorsolateral prefrontal cortex; BA9=Brodmann area 9; BA10=Brodmann area 10; BA24=Brodmann area 24; ACC=anterior cingulated cortex; IC=
insular cortex; SZ=schizophrenia; BD=bipolar disorder; MDD=major depressive disorder; HC=healthy control; P=psychotic; NP=non-psychotic; 2DE=two dimensional electrophoresis;
2D-DIGE=two dimensional difference gel electrophoresis; MALDI-TOF=matrix assisted laser desorption/ionization-time of ﬂight mass spectrometry; GELC-MS/MS=in gel digestion in 1 dimen-
sional gels followed by tandem mass spectrometry; iTRAQ=isobaric tagging for relative and absolute quantiﬁcation mass spectrometry; LC-MSE= liquid chromatography mass spectrometry in
expression mode. CPA=computational pathway analysis, VD=Validation, IB= immunoblot, TR=technical replication, FA=functional assay, Refs: [1] Johnston-Wilson et al. (2000), [2] Prabakaran
et al. (2004), [3] Beasley et al. (2006), [4] Clark et al. (2006), [5] Novikova et al. (2006), [6] Pennington et al. (2008a), [7] Clark et al. (2007), [8] Sivagnanasundaram et al. (2007), [9] Behan et al. (2009),
[10] Pennington et al. (2008b), [11] Focking et al. (2011), [12] Martins-de-Souza et al. (2010), [13] Martins-de-Souza et al. (2012), [14] Chan et al. (2011), [15] Wesseling et al. (2013).
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Prabakaran et al., 2004; Beasley et al., 2006; Clark et al.,
2006; Novikova et al., 2006; Sivagnanasundaram et al.,
2007; Pennington et al., 2008a, b; Behan et al., 2009;
Martins-de-Souza et al., 2010, 2012; Chan et al., 2011;
Focking et al., 2011; Wesseling et al., 2013). These proteo-
mic alterations are more and less robust across different
studies and psychiatric disorders. However, it still re-
mains to be determined whether the effects seen on
these pathways represent true disease modiﬁcations,
or if they are detected due to the higher relative con-
centrations of such proteins in neuronal cells, thus biasing
the interpretation of the ﬁndings at the pathway level.
In addition, the proposed pathways fall into broad cat-
egories. One way of overcoming this problem would be
to carry out bioinformatic pathway analysis using geneset
enrichment analyses applied on a protein level. This
could also lead to identiﬁcation of shared biological func-
tions across different studies. In addition, the low sample
numbers associated with most post-mortem brain studies
have resulted in uncertainty in the statistical robustness
of the ﬁndings. Thus, most of the functional and pathway
data inferred from such studies still require validation.
Nevertheless, most of the ﬁndings from these inves-
tigations show signiﬁcant convergence with candidate
genes, which have been implicated in genomic (English
et al., 2011) or transcriptomic (Prabakaran et al., 2004)
studies of the same or related post-mortem brain samples.
There are other limitations which make interpretation
of these ﬁndings difﬁcult. Firstly, with the use of post-
mortem material comes the potential of confounding
effects, including differences in post-mortem intervals,
time and method of storage and other variables. Further-
more, virtually all psychiatric patients are likely to have
received various medications and suffered co-morbidities
prior to death. Also, few studies have carried out techni-
cal validation of the ﬁndings using orthogonal proteomic
methods or functional follow up studies, due to the low
availability of high quality post-mortem brain tissues.
We suggest that the application of multiple platforms in
combination will not only provide a deeper insight into
the affected protein pathways, but this will also enable
cross-validation of the ﬁndings and investigation of the
abnormalities in a system-based way. Furthermore, we
propose that future studies employ biomaterials which
can act as surrogates of brain tissue and can be obtained
easily from living patients (see below). This will help to
overcome the numerous confounding factors associated
with post-mortem materials and should also lead to
increased statistical power of the studies.
Proteomic proﬁling of serum and plasma
Serum and plasma have been used increasingly in proteo-
mic studies of psychiatric disorders. The rationale for this
stems from the emerging fact that psychiatric disorders
are whole body diseases. The ﬁelds of endocrinology, im-
munology and biochemistry have shown that the brain is
integrated in fundamental bodily functions, which is also
reﬂected in changes in the composition of blood proteins
and other bioactive molecules. One of the best examples is
the ﬁght-or-ﬂight reﬂex (Tsigos and Chrousos, 2002)
which begins with perception of danger, followed by
release of a cascade of hormones such as corticotrophin
releasing factor, adrenocorticotrophic hormone and cor-
tisol. These hormones circulate throughout the body to in-
crease blood pressure and glucose levels in preparation
for the muscular actions required in the response.
Other well known processes mediated through the blood-
stream which can affect both brain and peripheral func-
tion include the regulation of food intake (Mastorakos
and Zapanti, 2004), immune system dysfunction
(Spathschwalbe et al., 1994), metabolic disorders and
insulin resistance (Pasquali et al., 2006; Reagan, 2007;
Solas et al., 2010). Furthermore, the bloodstream com-
prises a large repository of proteins and metabolites
which are secreted or leaked from surrounding tissues,
blood cells and organs (Anderson and Anderson, 2002;
Zhang et al., 2007).
One advantage of using bio-ﬂuids is that the majority
of the constituent proteins are soluble. Therefore, the
usual solubilization steps prior to proteomic analyses of
tissues are not needed. However, there are other major
challenges associated with their use, such as the high dy-
namic range of protein and peptide abundances, which
span more than 10 orders of magnitude (Anderson and
Anderson, 2002). Accordingly, optimized methodologies
have been established to address this technical limitation
using extensive fractionation (Guerrier et al., 2005; Pan
et al., 2007) and depletion of the 12–14 most abundant
proteins. The latter removes approximately 98% of the
total protein mass (Levin et al., 2010a) and allows in-
creased identiﬁcation and quantiﬁcation of larger num-
bers of low-abundance proteins (Liu et al., 2006;
Schutzer et al., 2010). However these approaches intro-
duce technical variability and can also lead to unwanted
depletion of some proteins through protein–protein inter-
actions with depleted high abundance proteins, as de-
scribed previously (Koutroukides et al., 2011).
One way of overcoming these problems is through
the use of several assay systems which offer a means of
targeted proteomic proﬁling of several hundred analytes
in serum or plasma with high sensitivity, such as the
multiplex immunoassay platforms. These methods
have already been successfully applied in clinical studies
of various diseases, including psychiatric disorders
(Chandler, 2003; Domenici et al., 2010; Schwarz et al.,
2012). In these methods, the samples are added to red/in-
frared dye-coded microspheres containing covalently
bound antibodies that target speciﬁc proteins. After
subsequent incubation with a secondary antibody with
a covalently-bound ﬂuorescent label, the mixtures are
passed through a ﬂow cytometry instrument for identiﬁ-
cation of the coded antibody-microspheres and quantita-
tion of the bound analytes. This method has the
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advantage of high sensitivity, high throughput capacity
and ease of use in the clinic.
Most of the mass spectrometry-based analyses of
serum and plasma from psychiatric patients have resulted
in identiﬁcation of high abundance proteins involved in
molecular transport, including apolipoproteins, ferritin
and transthyretin, and the clotting cascade, such as com-
plement components (Fleming et al., 2009; Levin et al.,
2010b; Jaros et al., 2012; Li et al., 2012). In a complemen-
tary manner, the use of multiplex immunoassay plat-
forms allows analysis of molecules such as hormones,
growth factors and cytokines, which are lower in abun-
dance. Two separate groups have used this platform
for proﬁling plasma (Yang et al., 2006; Levin et al.,
2010b) and serum (Schwarz et al., 2010, 2012; Guest
et al., 2011) from schizophrenia patients and controls,
and found common changes, including effects on brain-
derived neurotrophic factor (BDNF), acute phase re-
sponse proteins, insulin, prolactin and growth hormone.
However, considerable further work is required to
maximize the impact of these ﬁndings, as none of
these potential serum biomarkers have been developed
for routine use in the clinical or pharmaceutical company
environments. The following sections indicate novel tech-
nological approaches which may help to achieve better
translation of proteomic ﬁndings into clinical use, or for
applications in drug discovery and development.
Innovative approaches
Phosphoproteomics
Post-translational modiﬁcations such as phosphorylation
are critical for altering the activity, cellular localization,
turnover and interaction of proteins. For example,
changes in the phosphorylation levels of the cAMP re-
sponse element-binding protein have been observed in
patients who respond to psychiatric medications com-
pared to non-responders (Koch et al., 2002). Improve-
ments in mass spectrometry methods have now made it
possible to identify thousands of phosphorylation sites
on proteins with high precision (Huttlin et al., 2010),
and recent data suggest that more than half of the pro-
teome might be regulated by phophorylation and
de-phosphorylation cycles (Lemeer and Heck, 2009).
Multidimensional liquid chromatography (MDLC)
mass spectrometry methods have been employed in
‘bottom-up’ workﬂows (Fig. 1). These methods combine
prior enrichment of phosphopeptides or phospho-
proteins using strong cation exchange (SCX) (Ballif
et al., 2004), hydrophilic interaction chromatography
(HILIC) (Albuquerque et al., 2008; McNulty and Annan,
2008), electrostatic repulsion liquid chromatography
(ERLIC) (Alpert, 2008) and strong anion exchange (SAX)
(Nuhse et al., 2003). Common methods for phospho-
peptide enrichment include chemical afﬁnity tag deri-
vatization, selective chromatographic enrichment of
phosphopeptides or the application of linked-scan mass
spectrometer acquisition methods relying on diagnostic
ions speciﬁc to phosphopeptides. Chemical derivatization
techniques exploit the reactivity of the phosphate func-
tional group. For example, beta-elimination of phospho-
serine and phosphothreonine, yielding dehydroalanine
or beta-methyldehydroalanine, can be induced by high
pH conditions. The products are then modiﬁed by chemi-
cal addition of afﬁnity tags (Oda et al., 2001) or stable iso-
topes (Goshe et al., 2002) for quantitation purposes.
Chromatographic methods for phosphopeptide enrich-
ment include immobilized metal ion (e.g. Fe3+ (Posewitz
and Tempst, 1999; Villen and Gygi, 2008), Ga3+
(Posewitz and Tempst, 1999), Zr4+ (Zhou et al., 2006),
Ti4+ (Zhou et al., 2008)) afﬁnity chromatography (IMAC),
TiO2-based phosphopeptide enrichment (Pinkse et al.,
2004), phosphotyrosine immunoprecipitation (Rush
et al., 2005) and soluble polymer-based phosphopeptide
enrichment. More advanced technologies include the
use of Ti4+-based IMAC enrichment (Zhou et al., 2011)
or immunoprecipitation of peptides containing the target
sequences of speciﬁc kinases (Moritz et al., 2010). The Zr4
+/Ti4+ IMAC approaches use a phosphate group as the
coordinating ligand, which confers higher speciﬁcity
compared to traditional metal oxide and Fe3+ IMAC
approaches (Zhou et al., 2006, 2008). Most remarkably,
a recent direct comparison showed that a novel
Ti4+-based IMAC approach was superior to other
methods by enabling identiﬁcation of around 5000 unique
phosphopeptides from 400 μg of HeLa cell lysate digest
(Zhou et al., 2013). This approach holds great potential
to provide greater insight into alterations affecting
phosphorylation cascades in neuropsychiatric research
(Martins-de-Souza et al., 2011).
Although there have been considerable advances in the
development of phosphoproteomics techniques there are
still limitations that need to be considered. Sample prep-
aration is often complex and requires relatively large
quantities, and the correct interpretation of phosphoryla-
tion dynamics always requires normalization by protein
expression changes (Wu et al., 2011) In addition, the
scientiﬁc community still have not reached a consensus
regarding standardization of phosphoproteomic data
and the approaches needed for data gathering, analysis,
storage and sharing. Finally, appropriate follow-up
experiments are required to ascertain the functional sign-
iﬁcance of identiﬁed phosphorylation sites.
Problems can be addressed by targeted phospho-
proteomic analysis using MRM coupled with automated
sample preparation methods. This has shown promise
for improving sensitivity and throughout. The future de-
velopment of such MS-based assays could enable this
technique to become an alternative approach in clinical
applications when antibody reagents are not easily
generated.
Although mass spectrometry methods are useful for
phosphoproteomic investigations, a recent study used a
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phospho-speciﬁc ﬂow cytometry technique as an alterna-
tive for identiﬁcation of disease-associated signalling ab-
normalities (Krutzik and Nolan, 2003; Perez and Nolan,
2006). In this method, cells derived from patient and
control samples were stimulated together to activate
intracellular signalling cascades. Subsequently, the cells
are ﬁxed with paraformaldehyde to freeze the signalling
events for analysis and then permeabilized for staining
with ﬂuorescently-labelled antibodies speciﬁc for cell sur-
face markers or for the phosphorylated forms of speciﬁc
signalling proteins before ﬂow cytometry analysis.
Selected reaction monitoring
A current bottleneck in the discovery of protein biomar-
kers for disease is the development of suitable methods
for validation. This is critical before too much time and
money are invested in biomarker candidates which turn
out to be non-reproducible. Thus far most studies have
used antibody-based methods such as immunoassays
and Western blot analyses for conﬁrming the results of
proteomic proﬁling studies. However, these methods re-
quire the availability of speciﬁc antibodies, which is not
always a viable option.
Over recent years, a ‘bottom-up’ liquid chromatogra-
phy SRM mass spectrometry approach has emerged
which aims to overcome this bottleneck for targeted
quantiﬁcation of protein biomarker panels. This method
is already in use for quantitation of low molecular weight
analytes (<1000 Da) in pharmaceutical, clinical and en-
vironmental applications (Gergov et al., 2003). However,
it has recently been optimized for peptides and is being
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Fig. 1. (a) In SRM, a triple quadrupole MS ﬁlters selected predeﬁned mass-to-charge (m/z) values corresponding to intact and
fragment ions of the peptide. The second quadrupole serves as a collision cell. (b) Comparison of SRM and SWATH-MS
data-independent acquisition. Left: SRM monitors unique combinations of multiple peptide and fragment ions in speciﬁc time
windows (horizontal black arrows). Right: The SWATH-SRM method involves consecutive acquisition of high resolution, accurate
mass fragment ion spectra during the entire chromatographic elution (retention time) range. It repeatedly steps through discrete
precursor isolation windows of 25 Da width (black double arrows) across the 400–1200m/z range. The series of isolation windows
acquired for a given precursor mass range is referred to as a ‘swath’ (red shading). (c) SRM and SWATH-MS approaches can be
used to simultaneously investigate multiple components of a single protein network. The example shows the targets in the
glutamate receptor signalling pathway, which is known to be affected in schizophrenia.
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used increasingly as a targeted mass spectrometry
method to determine relative and absolute protein levels
in biological samples (Anderson and Hunter, 2006;
Keshishian et al., 2007, 2009). SRM experiments are typi-
cally run on triple quadrupole mass spectrometers. The
ﬁrst quadrupole (Q1) is used to scan and ﬁlter ions,
while the second quadrupole (Q2) is used as a collision
cell to fragment the peptide and to transmit ions to
the third quadrupole (Q3), where further scanning and
ﬁltering occurs. Transitions of the precursor and fragment
ions in Q1 and Q3, respectively, can then be selected,
which gives SRM a high dynamic range, accuracy and
sensitivity for peptide detection in complex samples com-
pared to traditional approaches (Addona et al., 2009).
A number of targeted SRM assays have been developed
which can analyse up to 100 proteins in a single ex-
periment. For example, SRM was used for measurement
of 67 putative cardiovascular disease biomarkers
over the concentration range of 100 ng/ml to 41mg/ml
(Domanski et al., 2012). Absolute quantitation can be
achieved by incorporation of synthetic stable iso-
tope-labelled standard peptides spiked into the samples
designated for analysis. The low development costs,
multiplexing capability and high sample through-put of
SRM should help in the veriﬁcation and validation stages
of the protein biomarker pipeline and provide a potential
platform for clinical use. However, it should be noted
that immunoassay approaches can still outperform SRM
methods in terms of dynamic range and sensitivity of
protein biomarkers in serum and plasma. Thus, a major
step forward would be an increase in the sensitivity of
SRM-based assays and a move towards more user
friendly conﬁgurations to facilitate ease of use in the
clinic.
In attempts to improve the lower limit of the detection
range of SRM, techniques such as stable isotope stan-
dards, capture by anti-peptide antibodies (SISCAPA)
and high-pressure high-resolution separations with intel-
ligent selection and multiplexing (PRISM) (Whiteaker
et al., 2010; Shi et al., 2012) have been developed. Both
these methods use immune-afﬁnity isolation of the
targeted peptides to enhance sensitivity. In addition, a
novel targeted data analysis strategy has emerged
which allows consistent and accurate quantiﬁcation of
proteomic data produced in SRM experiments by mining
the complete fragment ion records generated during data-
independent acquisition (Gillet et al., 2012; Hopfgartner
et al., 2012). This alternative method is called sequential
window acquisition of all theoretical fragment-ion spectra
(SWATH) mass spectrometry. In this technique, sequen-
tial precursor ion windows can be recorded over the
entire chromatographic range to collect the same spectra
of precursor and fragment ions over a deﬁned collision
energy range (Fig. 1). The resulting high-speciﬁcity frag-
ment ion maps can be queried for the presence and quan-
tity of protein targets using a priori information contained
in spectral libraries containing fragment ion signals, their
relative signal intensities and chromatographic concur-
rence. This offers the advantage of increasing the poten-
tial number of peptide targets 10-fold in a single mass
spectrometry run compared to standard SRM ap-
proaches, and circumvents the tedious manual develop-
ment of SRM assays.
Further development of these methods to investigate
multiple components of protein networks should help
to advance our knowledge in the systems biology nature
of diseases such as schizophrenia. For example, a number
of studies have indicated effects on myelin (Walterfang
et al., 2011) and oligodendrocyte (Edgar and Sibille,
2012) function in schizophrenia. This could be investi-
gated further in studies of post-mortem brain tissues
from schizophrenia patients and as multiplex readout in
studies of preclinical models by developing SRM panels
targeting multiple components of these pathways. In
this case, this could include assays for myelin proteolipid
protein, myelin basic protein, myelin-associated glyco-
protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase
(Fulton et al., 2010).
Cell based models
The development of novel drugs for psychiatric illnesses
has come to a standstill due to difﬁculties of classifying
symptoms and an inadequate understanding of the affec-
ted molecular pathways in patients. Moreover, a high
drug attrition rate has resulted from a current focus on
pathophysiologies identiﬁed in animal models, which
are not readily translated to the human disease. Recent
studies indicate that data with higher translational rel-
evance can be obtained using biological samples such
as blood serum and cells, which can be obtained directly
from patients. Serum contains molecules such as hor-
mones and cytokines, which can act as molecular read-
outs of brain function, and peripheral blood cells
(PBMCs) express important targets which are found in
the brain including neurotransmitter, hormonal and cyto-
kine receptors, and the corresponding signalling path-
ways (Gladkevich et al., 2004). Previous studies have
shown that PBMCs can be used for identiﬁcation of bio-
markers related to altered energy metabolism in ﬁrst-
onset antipsychotic–naïve schizophrenia patients and
healthy controls (Herberth et al., 2011). The main objec-
tive is now to test such cells as potential novel screening
platforms for drug proﬁling, using reporter systems for
activation of receptor signalling cascades. The functional
responses measured using this cell-based system include
calcium ﬂux, phosphorylation of signalling cascades,
mitochondrial membrane potential, receptor and trans-
porter expression/internalization, GPCR ligand binding,
apoptosis, oxidative stress, proliferation and cell
cycle properties (Valet, 2006). All of these processes are
known to be affected in schizophrenia and bipolar dis-
order (BD). For example, disease signatures can be iden-
tiﬁed by comparison of speciﬁc protein kinase signalling
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cascades using PBMCs from psychiatric patients and con-
trols after addition of control drugs. Testing can also
be carried out after addition of current psychiatric medi-
cations or potential novel therapeutic approaches includ-
ing anti-inﬂammatory, anti-diabetic and anti-oxidant
drugs (Fig. 2). The resulting activation patterns can then
be considered as a functional barcode which can be
used to stratify patients with respect to diagnosis, prog-
nosis, treatment response and side effects. Likewise,
screening for novel targets will be possible with this sys-
tem. Taken together with traditional proteomic signatures
obtained by LC-MSE analysis of cell lysates, novel phos-
phoproteomic approaches and multiplex immunoassay
proﬁling of cell supernatants, this could lead to a preclini-
cal model with companion biomarker read-outs for use
in studies of psychiatric disorders and in the discovery
of new drug targets and medications.
Another potential model which can be obtained di-
rectly from living patients is functional neuron-like cells
from reprogrammed ﬁbroblasts. This is achieved by intro-
duction of key transcription factors into ﬁbroblasts to pro-
duce induced pluripotent stem cells (iPSCs) which can be
differentiated into neuronal cells (Marchetto et al., 2010;
Qiang et al., 2011; Israel et al., 2012). A proof-of-principle
study generated iPSC-derived neurons from schizo-
phrenia patients with a disrupted in schizophrenia 1
(DISC1) mutation, and found that these cells recapitu-
lated features found in schizophrenia, such as reduced
neuronal connectivity, reduced outgrowths from soma
and reduced post-synaptic density 95 (PSD95) levels rela-
tive to controls (Brennand et al., 2011; Chiang et al., 2011).
Interestingly, the gene expression data indicated effects
on pathways which have not been described previously
in schizophrenia, including notch signalling, cell adhesion
and Slit-Robo-mediated axon guidance. Pedrosa and
co-workers generated iPSCs from three schizophrenia
patients and reported that the resulting neurons ex-
pressed a number of transcription factors, chromatin
remodelling proteins and synaptic proteins relevant to
schizophrenia (Pedrosa et al., 2011).
It is likely that iPSC-derived neuronal cells from psy-
chiatric patients and controls can also be proﬁled using
the combined proteomics and cytomics approach de-
scribed above. However, in the case of the derived neuro-
nal studies, other cellular processes such as differentiation
can be investigated to potentially shed light on hypoth-
eses regarding schizophrenia as a neurodevelopmental
disorder (Piper et al., 2012).
Mass cytometry
There have been numerous studies using ﬂow cytometry
methods in the study of psychiatric diseases (Baier et al.,
2009; Brito-Melo et al., 2012; Muller et al., 2012). Recently
a rapid quantitative cell-counting method for frozen
unﬁxed post-mortem brains using a ﬂow cytometer was
developed (Nihonmatsu-Kikuchi et al., 2011). Using this
approach, the authors were able to count stained nuclei
and measured their sizes in frontopolar and inferior tem-
poral cortices from patients with schizophrenia and
BD. Overall, this provided simple means of rapid cell-
counting for quantifying the densities of neurons, oligo-
dendrocytes, astrocytes, microglia and endothelial cell
nuclei comprehensively. A newly-developed technology,
called mass cytometry, combines ﬂuorescence-based
ﬂow cytometry with inductively coupled plasma
PBMCs
Drug
Cell media
Cell lysates
Intact cells
Multiplex
immunoassay
Mass
spectrometry
Cytomics
Measurement of
cellular responses
(Barcoding)
Fold 
change
8.
00
2.
00
1.
50
1.
20
1.
10
1.
05
0.
95
0.
90
0.
80
0.
60
0.
40
0.
00
IL.1b
IL.2
IL.4
IL.5
IL.6
IL.8
IL.10
IL.12p70
IL.17aR
esl_100
R
el_10
R
esl_1
G
lyb_100
G
lyb_10
G
lyb_1
R
apa_2.74
R
apa_0.27
R
apa_0.032
Pred_100
Pred_10
Pred_1
(a) (b)
Fig. 2. (a) General scheme to explore functional aspects of drug effects on cells using a combination of proteomic (mass
spectrometry and multiplex immunoassay) and cytomic methods. (b) Generation of cellular barcodes showing impact of different
drugs and doses (x-axis) on cytokine response (y-axis) in PBMCs isolated from four control subjects (unpublished ﬁndings). Drugs
were tested under stimulated conditions using SEB/anti-CD28/LPS. Only signiﬁcant changes (p<0.05, Wilcoxon rank-sum test) of at
least 5% are shown. The colours correspond to fold changes as shown in the legend. Black indicates that respective hit was not
available (NA), not signiﬁcant (NS) or FC was too low to have relevant biological effect (FC<5%). Comparison of barcodes from
control subjects and psychiatric patients can give a new insight into the affect pathways and also identify potential drug targets for
development of novel pharmaceutical treatments. Pred=prednisolone; Rapa=rapamycin; Glyb=glybenclamide; Res=resveratrol.
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time-of-ﬂight mass spectrometric analysis of single cells.
This method makes use of transition element isotopes
as chelated antibody tags for target epitopes on and with-
in cells (Fig. 3). The method enables the simultaneous
measurement of 34 cellular parameters instead of the
6–10 parameters normally obtained using standard ﬂow
cytometry platforms (Perfetto et al., 2004). This is due
to the fact that mass cytometry is affected less by inter-
ference from spectral overlap compared to standard
ﬂow cytometry approaches (Lou et al., 2007; Bandura
et al., 2009).
This method has been successfully employed for
measurement of 34 parameters in cells derived from
healthy human bone marrow, resulting in a system-wide
view of normal human hematopoietic and immune sig-
nalling following ex vivo stimulation and inhibition
using various compounds (Bendall et al., 2011). This
facilitated identiﬁcation of cell-speciﬁc signalling pheno-
types of drug action which could be mapped to speciﬁc
pathways. The resulting dataset of bone marrow cells
captured snapshots of the cell types and corresponding
regulatory signalling responses present throughout devel-
opment from early progenitors to lineage-committed
cells. Given that this technology allows determinations
of up to 100 parameters per cell (Ornatsky et al.,
2010), it should help to increase our understanding
of cell type-speciﬁc signalling responses in complex net-
works such as the immune system (Bandura et al.,
2009). The method also helps to overcome some of the
existing challenges in ﬂow cytometry with regards to
spectral interference, ﬂuorescent dye quenching and
autoﬂuorescence. Although there is still room for im-
provement due to low sensitivity and inadequate avail-
ability of antibodies, the advantages include high
multiplicity of biomarker detection, absolute quantiﬁca-
tion, absence of detection channel overlap, no sample
matrix effects, simpliﬁed measurement protocols and
lower sample and reagent consumption. These factors
should help to revolutionize the use of ﬂow cytometry
methods in psychiatric research by leading to the
identiﬁcation of system-wide views of abnormal signal-
ling in humans suffering from these disorders. Further-
more, the methods could also be applied to studies of
the disease and psychiatric drug mechanisms of action
using PMBCs or iPSC-derived neurons, as described
above.
Subcellular proteomics
Current proteomic techniques normally look at the pro-
teome at speciﬁc endpoints as in post-mortem brain stu-
dies. Although such studies are valuable, psychiatric
disorders are considered to be neurodevelopmental disor-
ders and thus studies over distinct time frames could lead
to novel insights into the aetiologies. The use of novel
cellular models, such as patient-derived iPSC and
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Fig. 3. Mass cytometry enables high-dimensional immuno-phenotyping of signalling behaviour in single cells. Antibodies coupled
to distinct, stable transition element isotope conjugates are sprayed as single-cell droplets into inductively-coupled argon plasma at
5500 K to vaporize each cell and ionize the atoms. Resulting elemental ions are sampled by MS-TOF and quantiﬁed, enabling
measurement ∼1000 cells/s. The approach is able to discriminate between cell types and analyse intracellular signalling pathways in
response to treatment. Data can be subjected to unsupervised cluster analysis (SPADE), which identiﬁes distinct phenotype
populations and determines the relationships based on nearest neighbour populations. Spade plots are shown representing the
expression of speciﬁc markers across all clusters. The plots for associated markers can be overlaid to create plots to visualize
pathway activation.
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neuronal cells mentioned above, makes it possible to in-
vestigate differences in the levels of proteins and their
subcellular location during the differentiation process.
This is also of interest in other ﬁelds of medicine, since
protein dynamics and localization can determine cellular
function (Schurov et al., 2004; Dranovsky and Hen, 2007;
Mackie et al., 2007).
Approaches studying the subcellular distribution
of proteins include the puriﬁcation of speciﬁc organelles
and characterization of their protein compositions. A pre-
vious fractionation study investigated the protein com-
position of human nucleoli over a series of time points
following various drug treatments (Andersen et al.,
2002). Although organelle-based approaches provide
valuable information about speciﬁc subcellular compart-
ments in isolation, methods have now been developed
to obtain a system-wide view of proteome dynamics.
With this in mind, a stable isotope labelling of amino
acids in cell culture (SILAC) -based approach has been
developed for quantifying cellular subproteomes and
for measuring the dynamics of proteome translocation
in response to stimulation. The method involves sub-
cellular proteomic comparison of parallel cell lines
grown on different SILAC isotopic label-containing
media. The ratio of SILAC labels for each peptide then
reﬂects the relative levels of the corresponding protein
in each compartment. In the case of the above study,
the authors were able to identify proteins which were
translocated in response to p53-dependent DNA damage
(Boisvert et al., 2010). Another spatial proteomic method
has combined subcellular fractionation with pulse-SILAC
to measure the synthesis, degradation and turnover rates
of proteins (Boisvert et al., 2012). Such methods could
also be applied to obtain information about abnormalities
in neuronal differentiation and synaptic dynamics in
patient-derived differentiated neurons or in whole brains
of animal models.
Another approach for investigating subcellular pro-
teomic changes is matrix assisted laser desorption/
ionization–time of ﬂight (MALDI-TOF) MS imaging.
This method allows investigation of the cellular distri-
bution of proteins, peptides, lipids, drugs and metabolites
in intact tissue sections. It provides important insights
into biological processes since the native distribution of
various proteins are minimally disturbed and histological
features remain intact throughout the analysis (Seeley
et al., 2011). Various forms of MALDI-TOF MS imaging
have already been successfully applied to characterize
the expression of proteins and other organic biological
compounds in diseased and normal brain slices
(Stoeckli et al., 2001; Todd et al., 2001; Coughenour
et al., 2004). The approach can also be used for detection
of pharmaceutical compounds in tissues, thereby provid-
ing target information (Reyzer et al., 2003; Khatib-Shahidi
et al., 2006; Hsieh et al., 2007). This approach has been
used to identify changes in protein expression in neurode-
generative disorders including Parkinson’s disease
(Pierson et al., 2004) and Alzheimer’s disease (Stoeckli
et al., 2002). The MALDI-TOF MS imaging approach
also allows high-resolution single-cell analysis and the
combined application of mass spectrometry scanning
can be used in a discovery mode to identify new protein
constituents of organelles and to determine how cells re-
spond to external cues such as different drug treatments
(Stoeckli et al., 2002). This could be particularly useful
in studies of the targets of psychiatric medications, as
the mechanisms of action of these drugs have not been
fully elucidated.
Future perspectives
This review has described recent advances using proteo-
mic biomarkers for increasing our understanding of the
molecular nature of psychiatric disorders. The ultimate
goal is to improve translation of preclinical ﬁndings to
clinical studies to enable development of improved treat-
ment strategies. One of the most important phases of this
endeavour is the validation of proteomic ﬁndings using
separate samples and through the use of orthogonal tech-
nologies such as SRM combined with SWATH mass
spectrometry. Using such methods it will be possible to
investigate effects on whole cellular pathways, such as
glutamate, serotonin and dopamine signal transduction,
which have been implicated in psychiatric disorders.
With this in mind, this review has discussed how it is
also important to associate biomarker changes with func-
tional read-outs based on whole cell analyses as the most
critical form of validation. Studies at the level of whole
cell biology can help to provide insights into systems bi-
ology. This could lead to a more integrative view of the
perturbed biological pathways, which are now thought
to affect many organ systems throughout the body.
In support of this, proteomic alterations have been iden-
tiﬁed in cerebrospinal ﬂuid (Bartolomucci et al., 2010),
serum (Guest et al., 2011; Schwarz et al., 2012), plasma
(Domenici et al., 2010), ﬁbroblasts (Wang et al., 2010)
and peripheral blood cells (Freudenreich et al., 2010;
Herberth et al., 2011) from living patients and from post-
mortem pituitary tissues (Krishnamurthy et al., 2012). In
addition, this review also described how the combined
use of subcellular analyses with proteomic proﬁling can
lead to insights into effects on translocation of proteins
between different cellular compartments in disease.
Most importantly, better translation of proteomic ﬁndings
to the clinic may be achieved using cellular models
such as PBMCs or iPSC-neurons, which can be obtained
directly from living patients. Analysis of these cells
using cytomic platforms can lead to functional barcodes
depicting changes in the state of cells in disease or in re-
sponse to drug treatment. In turn, this should lead to de-
velopment of novel therapeutic targets for drug
development and to the individualization of treatment
approaches, thereby increasing the chances of positive
therapeutic outcomes.
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